Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors

被引：0
|
作者：
Matthew T. Roe
David J. Moliterno
机构：
[1] Cleveland Clinic Foundation,
来源：
Journal of Thrombosis and Thrombolysis | 1999年 / 7卷
关键词：
Public Health; Acute Coronary Syndrome; Platelet Glycoprotein;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 257
页数：10
相关论文
共 50 条
  • [41] The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes
    Koller, CF
    HEART & LUNG, 2001, 30 (05): : 321 - 331
  • [42] The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes
    Bolognese, Leonardo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1217 - 1226
  • [43] Oral platelet glycoprotein IIb/IIIa inhibitors
    Kereiakes, DJ
    CORONARY ARTERY DISEASE, 1999, 10 (08) : 581 - 594
  • [44] Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes
    Serrano, CV
    Nicolau, JC
    Venturinelli, M
    Baracioli, LM
    Anders, RJ
    Cannon, CP
    Ramires, JAF
    CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (02) : 129 - 132
  • [45] Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes -: Gradient of benefit related to the revascularization strategy
    Roffi, M
    Chew, DP
    Mukherjee, D
    Bhatt, DL
    White, JA
    Moliterno, DJ
    Heeschen, C
    Hamm, CW
    Robbins, MA
    Kleiman, NS
    Théroux, P
    White, HD
    Topol, EJ
    EUROPEAN HEART JOURNAL, 2002, 23 (18) : 1441 - 1448
  • [46] Role of Oral Blockade of Platelet Glycoprotein IIb/IIIa on Neutrophil Activation in Patients with Acute Coronary Syndromes
    Carlos V. Serrano
    José C. Nicolau
    Margareth Venturinelli
    Luciano M. Baracioli
    Robert J. Anders
    Christopher P. Cannon
    José A. F. Ramires
    Cardiovascular Drugs and Therapy, 2003, 17 : 129 - 132
  • [47] Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?z
    Silva, Matthew
    Donovan, Jennifer
    Gandhi, Pritesh
    Volturo, Gregory
    VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (01) : 39 - 48
  • [48] Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil-platelet interactions in patients with acute coronary syndromes
    Serrano, CV
    Venturinelli, M
    Ramires, JAF
    Cannon, CP
    Nicolau, JC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 343A - 343A
  • [49] Efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes
    Sitges, M
    Bosch, X
    Sanz, G
    REVISTA ESPANOLA DE CARDIOLOGIA, 2000, 53 (03): : 422 - 439
  • [50] Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond
    Manoharan, G
    Adgey, AAJ
    HEART, 2001, 86 (03) : 259 - 261
12345